HUMAN IMMUNODEFICIENCY VIRUS INACTIVATOR
To provide a human immunodeficiency virus (HIV) inactivator that has high safety and also has HIV inactivating effect.SOLUTION: An HIV inactivator contains a lignin component at least containing a lignin derivative as an active ingredient. The mass ratio of the extraction component content to the me...
Gespeichert in:
Hauptverfasser: | , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; jpn |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To provide a human immunodeficiency virus (HIV) inactivator that has high safety and also has HIV inactivating effect.SOLUTION: An HIV inactivator contains a lignin component at least containing a lignin derivative as an active ingredient. The mass ratio of the extraction component content to the methoxyl group content is 0.0001-0.5 in terms of the solid content of the lignin component. The lignin derivative preferably at least contains ligninsulfonic acid. The methoxyl group content and the extraction component content are preferably 2.0 mass% or more and 1.7 mass% or less, respectively, in terms of the solid content of the lignin component.SELECTED DRAWING: None
【課題】本発明の課題は、安全性が高く、かつヒト免疫不全ウイルス(HIV)不活性化効果を有するHIV不活性化剤を提供することにある。【解決手段】本発明は、リグニン誘導体を少なくとも含むリグニン成分を有効成分とし、リグニン成分の固形分当たりの、抽出成分量のメトキシル基量に対する質量比が0.0001~0.5である、HIV不活性化剤を提供する。リグニン誘導体は、リグニンスルホン酸を少なくとも含むことが好ましい。リグニン成分の固形分当たりのメトキシル基量、リグニン成分の固形分当たりの抽出成分量は、それぞれ2.0質量%以上、1.7質量%以下が好ましい。【選択図】なし |
---|